Quest Diagnostics director sells $292,329 in shares
Alpha Vantage · Investing.com Australia · · AI-summarised by FinFlash
Quest Diagnostics director Gary Pfeiffer sold 1,203 shares for $292,329 on October 26, 2026, under a Rule 10b5-1 sales plan, with DGX trading at $245.62. The stock is up 44% year-to-date after strong third-quarter 2026 results that beat expectations on revenue and adjusted earnings per share. InvestingPro analysis suggests the shares are overvalued, a caution for investors weighing the rally.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.